Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1993 Apr;71(4):299-304.
doi: 10.1007/BF00184731.

Circulating intercellular adhesion molecule 1 as a new activity marker in patients with systemic lupus erythematosus

Affiliations

Circulating intercellular adhesion molecule 1 as a new activity marker in patients with systemic lupus erythematosus

E Kling et al. Clin Investig. 1993 Apr.

Abstract

To determine the value of soluble intercellular adhesion molecule 1 (sICAM-1) as a measure of disease activity in patients with systemic lupus erythematosus (SLE), 25 patients with SLE were studied in an active and in a less active state. Disease activity was assessed according to the New York Hospital for Special Surgery System (NYHSS) score. The levels of sICAM-1 were significantly higher in an active than in a less active state of the disease (P < 0.001). The correlation between ICAM and the NYHSS score was r = 0.3412 (P < 0.001) and that between NYHSS index and soluble interleukin-2 receptors (sIL-2R) was r = 0.6620 (P < 0.001). There was a good correlation between levels of sICAM-1 and sIL-2R (r = 0.6792, P < 0.001). Both sICAM-1 and sIL-2R were positively and significantly correlated with an increase in the erythrocyte sedimentation rate, but only sIL-2R levels were significantly correlated with increased dsDNA antibodies and with a decrease in serum complement factor C3. Our data suggest that sICAM-1 reflects disease activity in patients with SLE, but this parameter per se should not be used to guide the therapeutic decision in SLE patients suspected of suffering from exacerbation of disease.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Arthritis Rheum. 1991 Aug;34(8):937-44 - PubMed
    1. J Immunol. 1988 Nov 1;141(9):3043-9 - PubMed
    1. Arthritis Rheum. 1990 May;33(5):644-9 - PubMed
    1. Cell. 1987 Dec 4;51(5):813-9 - PubMed
    1. Adv Immunol. 1985;37:269-390 - PubMed

LinkOut - more resources